55304-73-9

Usage

Uses

Used in Pharmaceutical Industry:
2,6-Dichloropyridine-3-carboxaldehyde is used as an intermediate in the synthesis of various pharmaceuticals. Its unique structure and reactivity make it a valuable building block for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, 2,6-Dichloropyridine-3-carboxaldehyde serves as a key intermediate for the production of various agrochemicals. Its incorporation into these compounds can enhance their effectiveness in pest control and crop protection.
Used in Organic Synthesis:
2,6-Dichloropyridine-3-carboxaldehyde is used as a building block in the synthesis of various heterocyclic compounds. Its presence in these compounds can impart unique chemical and physical properties, making them suitable for a wide range of applications in different industries.

InChI:InChI=1/C6H3Cl2NO/c7-5-2-1-4(3-10)6(8)9-5/h1-3H

Upstream product

• 2591-86-8 N-Formylpiperidine 
• 2402-78-0 2,6-dichloropyridine 
• 55304-90-0 2,6-dichloro-3-(hydroxymethyl)pyridine 
• 70290-47-0 N,N-dimethyl-2,6-dichloronicotinamide 
• 68-12-2 N,N-dimethyl-formamide 
• 38496-18-3 2,6-dichloropyridine-3-carboxylic acid 
• 58584-86-4 ethyl 2,6-dichloronicotinate 

Downstream Products

• 55304-90-0 2,6-dichloro-3-(hydroxymethyl)pyridine 
• 901323-36-2 2,6-bis(3-trifluoromethylphenoxy)pyridine-3-carboxaldehyde 
• 1013647-52-3 2-chloro-6-(2,3-difluorophenyl)nicotinaldehyde 
• 1013647-47-6 2-chloro-6-[4-(trifluoromethyl)phenyl]nicotinaldehyde 
• 1013647-49-8 2-chloro-6-[4-chloro-3-(trifluoromethyl)phenyl]nicotinaldehyde 
• 1202503-17-0 2,6-dichloro-3-[(E)-[(2,4-dichlorophenyl)hydrazono]methyl]pyridine 
• 63725-52-0 6-chloro-1-methyl-1H-pyrazolo[3,4-b]pyridine 
• 1621705-00-7 5-(10-fluoro-5-hydroxy-5H-pyrido[2’,3‘:3,4]pyrrolo[1,2-a]indol-2-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1426389-61-8 4-(2-(4-(2,6-dichloropyridin-3-yl)-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidin-5-yl)thiazol-4-yl)benzonitrile 
• 1030377-66-2 2-methyl-6-{(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl}nicotinaldehyde 
• 926303-51-7 4-(6-chloro-5-formyl-pyridin-2-yloxy)-benzoic acid methyl ester 
• 871583-20-9 methyl 4,6-dichloro-1H-pyrrolo[3,2-c]pyridine-2-carboxylate 
• 58584-60-4 (2-amino-6-chloro-pyridin-3-yl)-methanol 
• 1374659-26-3 2,6-dichloro-3-(difluoromethyl)pyridine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS MUTANT IDH INHIBITORS

The present disclosure relates generally to compounds useful in treatment of conditions associated with mutant isocitrate dehydrogenase (mt-IDH), particularly mutant IDH1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against mutant IDH1 enzymes. Method of treating conditions associated with excessive activity of mutant IDH1 enzymes with such compound is disclosed. Uses thereof, pharmaceutical composition, and kits are also disclosed.

PRMT5 INHIBITORS AND USES THEREOF

Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described

HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF

Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and neurological disorders, including, but not limited to, e.g., psychosis, schizophrenia, depression, movement disorders, and Parkinson's disease.

CHEMOKINE RECEPTOR BINDING COMPOUNDS

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR4 or CCR5. In one aspect, these compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

PYRROLOPYRIDINES USEFUL IN THE TREATMENT OF INFLAMMATION

There is provided compounds of formula (I), wherein X1, R1, R2, Y1, Y2, Y3 and Y4 have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation.

Novel 1,4-benzodiazepine-2,5-diones as Hdm2 antagonists with improved cellular activity

The disruption of the p53-Hdm2 protein-protein interaction induces cell growth arrest and apoptosis. We have identified the 1,4-benzodiazepine-2,5-dione scaffold as a suitable template for inhibiting this interaction by binding to the Hdm2 protein. Several compounds have been made with improved potency, solubility, and cell-based activities.

1-(HETERO)ARYL-3-AMINO-PYROLLIDINE DERIVATIVES FOR USE AS MGLUR3 RECEPTOR ANTAGONISTS

The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.

NOVEL IMIDAZOLES WITH ANTI-INFLAMMATORY ACTIVITY

Compounds of formula I wherein: one of X or Y represents N and the other represents C; R1 represents hydrogen, methyl, halogen, cyano, nitro, -CHO, -COCH3 or -COOR4; R2 represents optionally-substituted aryl or heteroaryl; R3 represents C1-8 alkyl, C1-8 haloalkyl or -NR4R6; R4 represents hydrogen, C1-8 alkyl or arylC0-8 alkyl; R6 represents hydrogen, C1-8 alkyl, arylC1-8 alkyl, -COR8 or -COOR8; R8 represents C1-8 alkyl or C1-8 haloalkyl; aryl in the above definitions represents phenyl or naphthyl; and heteroaryl in the above definitions represents pyridine, pyrazine, pyrimidine or pyridazine, which can be optionally fused to a benzene ring. These compounds are useful as cyclooxygenase-2 inhibitors.

Le phenyl-lithium: nouvel agent de metallation du cycle pyridinique

Nucleophilic addition was the sole reaction of phenyl-lithium with a pyridinic ring; now the novel catalysed metallation, with phenyl-lithium, of many substituted pyridine compounds giving various derivatives in high yields with many different reagents, has been achieved.